The Bonami Lab in the Department of Medicine at VUMC

Bonami Lab

Bonami Laboratory

Division of Rheumatology and Immunology

Department of Medicine

Research Focus

Our overarching goal is to identify mechanisms by which autoantigen-specific B lymphocytes breach immune tolerance barriers to drive autoimmune disease.

 

Research Program

B lymphocytes in autoimmune disease: B lymphocytes are immune cells that attack pathogens like flu. Under the wrong circumstances, they can also target "self" proteins to cause autoimmune diseases. Autoantibodies signal this attack is happening, sometimes well before disease symptoms appear. Autoantibodies may directly cause tissue destruction, or they may simply serve as red flags of inappropriate autoreactive T cell-B cell interactions. Our primary research interest is to understand how self-reactive B lymphocytes expand in the repertoire to drive autoimmune disease.

Type 1 diabetes: Several autoantigens (self proteins) are targeted in type 1 diabetes, including insulin. Selective elimination of anti-insulin B lymphocytes prevents type 1 diabetes in a mouse model, highlighting this population of cells as an attractive therapeutic target. We are currently employing high-throughput approaches to interrogate this critical population of autoantigen-presenting cells in type 1 diabetes patients who are in the very early, pre-symptomatic stages of disease. These studies are being performed in collaboration with Daniel Moore, M.D., Ph.D. at Vanderbilt which serves as a T1D TrialNet center. Our long-term goal is to use innovative approaches to study and target this dangerous population of immune cells to hasten development of safe and effective therapies for this devastating disease.

B cells in T1D
 

FIGURE: B lymphocytes present insulin autoantigen to drive beta cell attack. Anti-insulin B lymphocytes internalize insulin autoantigen via the B cell receptor (BCR) and present insulin peptide to T cells (A). CD4 T cells produce inflammatory cytokines that promote CD8 T cell attack of beta cells. A small fraction of anti-insulin B lymphocytes differentiate to become antibody-secreting cells, either through T cell-dependent responses that drive somatic hypermutation and affinity maturation (B) or T cell-independent mechanisms (C). Autoantibody does not directly mediate beta cell destruction; rather, it signals T-B cell interaction.

 

10X


FIGURE: Phenotypic, transcriptional, and B cell receptor (BCR) repertoire profiling of autoimmune donors. The 10X Genomics platform was used to measure phenotypic (CITEseq), transcriptomic (RNAseq) and BCR repertoire (BCRseq) at the single cell level in donors at high risk for T1D and controls. Expanded BCR clones (not shown) were identified within transcriptionally and phenotypically defined B cell subsets in at-risk T1D donors.

 

Myositis: The myositis spectrum includes several clinical disease phenotypes. Histidyl tRNA anti-synthetase syndrome (HARS) is defined by autoantibodies that recognize this autoantigen, also called Jo-1. We are currently collaborating Rheumatology/Immunology Division clinical faculty, including Leslie Crofford, M.D. and Erin Wilfong, M.D., Ph.D. to investigate Jo-1-binding B cells using approaches outlined above to better understand how they breach immune tolerance to expand and differentiate to secrete Jo-1 autoantibody used clinically to diagnose HARS. We aim to develop new biomarkers and identify new pathways to target to selectively impair autoreactive B cell function as a means to limit disease progression and track favorable responses to new immune therapies in clinical trials.

Jo-1-binders flow

 

FIGURE: Jo-1-binding B cells are identified in patients with Histidyl tRNA anti-synthetase syndrome (HARS). Peripheral blood mononuclear cells were isolated. Flow cytometry identifies B cells that bind Jo-1-GST antigen in patients with either stable or active HARS, but not healthy control donors.

 

Immune checkpoint inhibitor-induced autoimmune sicca: Immune checkpoint inhibitors are used to treat cancer but can cause immune related adverse events (irAEs) such as autoimmune sicca in patients. Through collaboration with Douglas Johnson, M.D., M.S.C.I., an oncologist and Melanoma Research Program Director at Vanderbilt, we are building a cohort and technology to interrogate Ro52 and Ro60-binding B cells in patients who develop autoimmune sicca following ICI therapy. Our goal is to understand how immune tolerance breach differs between this acute form of autoimmunity with the more chronic form that occurs in patients with spontaneous autoimmune sicca in primary Sjogren's syndrome.